Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

Journal of Immunology

Volumn 165, Issue 7, 2000, Pages 3797-3803

  Nouri Shirazi, M ^a   Banchereau, J ^a   Bell, D ^a   Burkeholder, S ^a   Kraus, E T ^a   Davoust, J ^a   Palucka, K A ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIA CELL LINE; MELANOMA CELL; NORMAL HUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNOLOGY;

EID: 0034292406     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.7.3797     Document Type: Article

References (26)

1. Origin, maturation and antigen presenting function of dendritic cells
2. Dendritic cells and the control of immunity
3. Tumor immunology: The glass is half full
4. Dendritic cells
5. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
6. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
7. Immunotherapy of cancer with dendritic-cell-based vaccines
8. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
9. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
10. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
11. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
12. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells. B7 costimulation, and T helper cell 1-associated cytokines
13. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
14. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
15. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
16. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
17. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
18. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
19. Tumor-specific killer cells in paraneoplastic cerebellar degeneration
20. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
21. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
22. 3 integrin and requires intracellular and extracellular calcium
23. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
24. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
25. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
26. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine